AscellaHealth Releases Q1 2024 Specialty & Rare Pipeline Digesttm: Captures Data and Progress of Groundbreaking Therapies in 2024

AscellaHealth, a global healthcare and specialty pharmacy solutions organization, today released its latest Specialty & Rare Pipeline Digesttm, the industry's most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches, cell and gene therapies (CGT), biosimilars and generics. Continuing its tradition of providing a quarterly, complimentary, digital source of industry information to support the specialty drug market needs of all stakeholders and decision-makers, AscellaHealth captures essential information and updates on products that may impact treatment for millions of individuals worldwide who are affected by complex, chronic conditions or rare diseases.

"This comprehensive, timely report provides valuable insights and current data, reflecting the multitude of specialty products poised for introduction during the first quarter of 2024," says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. "We are impressed with this level of progress and pleased to share this information in support of the entire specialty pharmaceutical ecosystem."

The Specialty & Rare Pipeline Digesttm complements the role of AscellaHealth as a single-source industry partner, providing end-to-end, global solutions which result in the streamlined commercialization of specialty drugs, cost savings for clients and an optimal treatment journey for patients and family caregivers. Core Services include:

• Pre-Commercialization & Market Access
• Exclusive Distribution, Wholesale and 3PL Services
• International Specialty Pharmacy Fulfillment
• Comprehensive HUB and Patient Support Services
  • Custom Compliance and Persistency Programs
  • Streamlined Prior Authorizations
  • Technology-based Patient Engagement
  • Integrated Copay and Financial Assistance Programs
  • Real-time Rx Data and Analytics
• Specialty Pharmacy & Medical Benefit Management

Pointing to the quarterly Specialty & Rare Pipeline Digesttm as the industry's most comprehensive document detailing the recent branded specialty drug approvals, upcoming Food & Drug Administration (FDA) reviews and the CGT and biosimilars pipelines, Dea Belazi, CEO, AscellaHealth, states, "This educational material empowers stakeholders with important information that is intended to enhance treatment access, improve patient care and optimize clinical outcomes."

Access the latest Specialty & Rare Pipeline Digesttm here.

About AscellaHealth LLC
AscellaHealth, a global healthcare and specialty pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies. A recipient of numerous industry awards for innovation, including Deloitte Technology Fast 500tm and Inc. 5000, AscellaHealth's customized, patient-centric approach is built upon proprietary technology processes for end-to-end solutions to streamline the commercialization of specialty medications and proactively address unmet client needs, optimize clinical health outcomes and improve the quality of life for this patient population. AscellaHealth brings a rare and special perspective to all stakeholders. Visit www.AscellaHealth.com.